ECH1: A Potential Drug Target and Biomarker (G1891)

Target Name: ECH1

NCBI ID: G1891

ECH1

ECH1: A Potential Drug Target and Biomarker

Epigenetic changes, such as DNA methylation, play a crucial role in the regulation of gene expression and cellular processes. Alterations in epigenetic regulation have been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One promising approach to targeting these changes is to identify potential drug targets and biomarkers that can be modulated with therapeutic compounds. In this article, we focus on the potential drug target and biomarker ECH1, which has been identified through various epigenetic studies and experiments.

ECH1: A Potential Drug Target

ECH1, also known as HDAC1 or hDNAAC1, is a key enzyme in the DNA methylation pathway that is involved in the transfer of methyl groups from DNA to RNA. Methylation of gene promoters is a critical epigenetic modification that can regulate gene expression and play a role in the development of various diseases, including cancer. Therefore, modulating ECH1 activity could be a promising approach to treating diseases that are characterized by epigenetic alterations.

Several studies have demonstrated that modulating ECH1 activity can be a powerful tool for targeting epigenetic pathways in cancer cells. For example, ECH1 has been shown to play a role in the regulation of the expression of the tumor suppressor gene, TP53. Inactivated TP53 has been implicated in the development of numerous cancers, including breast, ovarian, and prostate cancers. Therefore, compounds that can modulate ECH1 activity have the potential to be useful anti-cancer agents.

In addition to its role in TP53 regulation, ECH1 has also been shown to play a critical role in the regulation of cellular processes that are critical for cancer development, such as cell division, apoptosis, and angiogenesis. Therefore, compounds that can modulate ECH1 activity may have utility in treating a variety of cancer types.

ECH1: A Potential Biomarker

The regulation of epigenetic pathways is a complex process that involves the interplay of multiple enzymes and factors. Identifying the epigenetic changes that occur in cancer cells and their corresponding biomarkers can be an important step in the development of new cancer therapies. ECH1 is a key enzyme in the DNA methylation pathway, and its regulation is critical for the development and progression of cancer. Therefore, ECH1 has the potential to be a valuable biomarker for cancer diagnosis and treatment.

One approach to identifying ECH1-related biomarkers is to use mass spectrometry (MS) to identify proteins that are regulated by ECH1. This approach has been used to identify a number of potential biomarkers for cancer, including the tumor suppressor protein, TP53, and the oncogene, PDGF-AA. These proteins are involved in various cellular processes that are critical for cancer development, and their regulation by ECH1 may provide valuable insights into the mechanisms of cancer development.

Another approach to identifying ECH1-related biomarkers is to use RNA sequencing (RNA-seq) to identify expressed genes that are regulated by ECH1. This approach has been used to identify a number of potential biomarkers for cancer, including genes involved in cell adhesion, migration, and angiogenesis. These genes may be involved in the regulation of cellular processes that are critical for cancer development, and their regulation by ECH1 may provide valuable insights into the mechanisms of cancer development.

Conclusion

In conclusion, ECH1 is a promising drug target and biomarker that has the potential to be useful in the treatment of a variety of cancer types. Modulating ECH1 activity may involve targeting various epigenetic pathways, including the regulation of TP53 regulation and the regulation of cellular processes that are critical for cancer development. Further research is needed to fully understand the mechanisms of ECH1 regulation and its potential as a drug

Protein Name: Enoyl-CoA Hydratase 1

Functions: Isomerization of 3-trans,5-cis-dienoyl-CoA to 2-trans,4-trans-dienoyl-CoA

The "ECH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets